EN 简 繁
EN 简 繁
EN 简 繁
Corporate Deck
CARsgen Therapeutics Corporate Deck
Feb 17, 2023
CARsgen Therapeutics Corporate Deck
Download
Presentations
iconDate Date
iconTitle Title
Jan 20, 2023
2023 ASCO GI | A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti CLDN18.2 Monoclonal Antibody (AB011), as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors
Dec 11, 2022
2022 ASH | Phase II Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Sep 29, 2022
2022 CAR TCR Summit
Jun 05, 2022
2022 ASCO | Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T‐cell therapy (CT041)
Jun 05, 2022
2022 ASCO | Multicenter Phase 1b Trial of Salvage CT041 CLDN18.2-specific Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma
Dec 13, 2021
2021 ASH | Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Dec 13, 2021
2021 ASH | Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors
Sep 19, 2021
2021 ESMO | CLDN 18.2-targeted CAR-T cell therapy (CT041) in patients with cancers of the digestive system